Retatrutide 10/20mg
Triple receptor agonist. The next generation of metabolic research.
Retatrutide is a triple receptor agonist, engaging GLP-1, GIP, and glucagon receptors simultaneously. It is being investigated in Phase 2 and Phase 3 clinical research (the TRIUMPH trial programme) examining metabolic and appetite-regulation pathways. Supplied for laboratory research purposes only.
Select size
£49.99
In stock · BAC Water included free
COA available on request · Same-day dispatch before 2pm
Retatrutide has been studied in Phase 2 and Phase 3 clinical trials investigating combined GLP-1/GIP/glucagon receptor agonism. Trial data is publicly available in peer-reviewed literature (e.g. NEJM) for those wishing to review methodology and findings independently.
Retatrutide binds and activates three receptors: GLP-1 (reduces appetite and slows gastric emptying), GIP (potentiates insulin release and fat metabolism), and glucagon (increases energy expenditure and hepatic glucose output). The combined effect produces greater metabolic impact than single or dual agonism alone.
Supplied as lyophilised powder. Reconstitute with bacteriostatic water before use. Requires refrigeration after reconstitution. For research purposes only.
For laboratory research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease. No claims are made regarding safety or efficacy in humans.